Le Lézard
Classified in: Health
Subjects: PDT, BFA, PET

Introducing myDogDNAge®: Revolutionary Canine Biological Age Test


Innovative epigenetic age test paves way for improved dog longevity.

TUSTIN, Calif., Oct. 24, 2023 /PRNewswire/ -- myDogDNAge® is a groundbreaking new epigenetic age test that sheds light on your dog's rate of aging and delivers key data points on their health. With a simple cheek swab, unlock insights like their:

Accurate epigenetic data will be a key piece in the quest for canine longevity.

myDogDNAge® offers insights that can revoutionize the pet health industry. Dr. Gary Richter, America's Favorite Veterinarian and author of Longevity for Dogs observed, "Utilizing accurate epigenetic data is going to be a key piece in our quest for canine longevity. Understanding how diet, supplementation, and interventional therapeutics affect a patient's epigenetic age will allow practitioners to customize therapeutics and learn how to extend the healthspan and lifespan of patients."

For veterinarians and companies developing or trialing new anti-aging therapies for dogs, myDogDNAge® represents a way to measure the impact of these interventions accurately and transparently. Dog owners can likewise use the test every 6 to 12 months to optimize lifestyle changes for their dog.

Results from myDogDNAge® testing could also "speak up" for your dog and catch health problems early, a significant help for pet parents. Results that significantly deviate from your dog's calendar age can signal an immediate need for a more thorough vet assessment.

"We created myDogDNAge® to empower pet owners with trustworthy data to help them enhance their dog's health more proactively," explained Dr. Xiaojing Yang, myDNAge® Lead Scientist.

myDogDNAge® is our love of dogs enhanced with the precise power of science. It uses the same technology behind myDNAge®, the leading biological age test for humans, now tailored to the specificity of the canine genome. Clinical studies conducted with myDogDNAge® are set to be published in peer-reviewed journals later this year.

"Aging is just one parameter of health," noted Dr. Yang, "We envision this test as the cornerstone of a wider series of tests, including the diagnosis of obesity and cancer."

myDogDNAge® retails for $250 per test and can be purchased exclusively at www.mydnage.com               

About myDNAge®

Launched in 2017, myDNAge® is the most accurate and precise direct-to-consumer biological age test. Our scientists collaborate closely with leading longevity researchers worldwide and explore the connection between epigenetics and health from metabolism to oncology.

Contact: 
Abigail Kang 
[email protected] 
(833) 693-6243

SOURCE myDNAge


These press releases may also interest you

at 05:15
The 'Global Cold Chain Market for Pharmaceuticals: Distribution by Type of Primary Packaging, Type of Secondary Packaging, Type of Usability and Key Geographical Regions: Historical Trends (2019-2022) and Forecasted Estimates (2023-2035)' report has...

at 04:00
At the European Congress of Radiology (ECR) 2024 in Vienna, United Imaging Intelligence (UII), a subsidiary of United Imaging Group, proudly presented its latest advances in medical AI technology. Renowned for its AI-driven healthcare applications,...

at 04:00
Walden Group, one of the main players in the area of healthcare logistics in Europe, officially enters the Italian market after  the acquisition of the two Italian companies XCM Healthcare, a healthcare logistics company, and Unitex, a...

at 04:00
111, Inc. ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for...

at 03:40
GENESIS Pharma, a regional biopharma company specialized in the commercialization of innovative medicines targeting severe and rare diseases in Central and Eastern Europe, announces an exclusive distribution agreement for the cancer medicine...

at 03:37
Royal Philips (AEX: PHIA), a global leader in health technology, and magnetic resonance imaging (MRI) software solutions company SyntheticMR (Linköping, Sweden) today announced the launch of Smart Quant Neuro 3D [1] ? a major advance in objective...



News published on and distributed by: